Prospects for Priligy as first mover CAR-T therapy for lymphoblastic leukemia in China
China is making significant strides in CAR-T innovation. Recently, Chongqing Precision Biotech received approval for Priligy (priscabtagene autoleucel) to treat pediatric and adolescent patients aged 3 to 21 years with CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).
With this approval, Priligy is expected to gain a first-mover advantage as a CAR-T therapy for second-line or later treatment of pediatric r/r B-ALL, according to pharma analytics company GlobalData.
Priligy is reportedly the first domestically developed autologous CAR-T cell product for pediatric patients with r/r B-ALL in China. Its approval was based on Phase II trial results, which showed an objective response rate (ORR) of 90.63% among 64 patients, with a median follow-up of 211 days.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze